Affiliation:
1. University Hospital Basel: Universitatsspital Basel
2. SolidarMed
3. Swiss Tropical and Public Health Institute: Schweizerisches Tropen- und Public Health-Institut
4. University of Basel: Universitat Basel
5. Government of Lesotho Ministry of Health
Abstract
Abstract
Background
Type 2 diabetes (T2D) poses a growing public health burden, especially in low- and middle-income countries (LMICs). Task-shifting to lay village health workers (VHWs) and the use of digital clinical decision support systems (CDSS) are promising approaches to tackle the current T2D care gap in LMICs. However, evidence on the effectiveness of lay worker-led T2D care models, in which VHWs initiate and monitor drug treatment in addition to community-based screening and referral services, is lacking.
Methods
We are conducting a cluster-randomized trial nested within the ComBaCaL (Community-Based Chronic Disease Care Lesotho) cohort study (NCT05596773) using the trial within cohort (TwiC) design to assess the effectiveness of a VHW-led, CDSS-assisted T2D care model in rural Lesotho. Participants are non-pregnant members of the ComBaCaL cohort study with T2D. The ComBaCaL cohort study is conducted in approximately 100 villages in two rural districts in Lesotho and is managed by trained and supervised VHWs. In intervention villages, VHWs offer a community-based T2D care package including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS to participants who are clinically eligible, as well as treatment support to participants who prefer or clinically require facility-based T2D care. In control clusters, all participants will be referred to a health facility for T2D management. The primary endpoint is the mean glycosylated haemoglobin (HbA1c) 12 months after enrolment. Secondary endpoints include the 10-year risk for cardiovascular events estimated using the World Health Organisation risk prediction tool.
Discussion
The trial was launched on May 13, 2023, and has enrolled 194 participants at the date of submission (August 9, 2023). To our knowledge, the trial is the first to assess task-shifting of T2D care to VHWs at community level, including the prescription of first-line antidiabetic, lipid-lowering, and antiplatelet medication in sub-Saharan Africa, and will thus provide the missing evidence on the effectiveness of such a T2D care model in this setting. The study is operating within the established Lesotho VHW program. Similar community health worker programs which exist across sub-Saharan Africa may benefit from the findings.
Trial registration
The trial has been registered on clinicaltrials.gov (NCT05743387; February 24 2023).
Publisher
Research Square Platform LLC
Reference62 articles.
1. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun H;Diabetes Res Clin Pract,2022
2. The double burden of diabetes and global infection in low and middle-income countries;Dunachie S;Trans R Soc Trop Med Hyg,2019
3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
4. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes;Kolb H;BMC Med,2017
5. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025;Lin X;Sci Rep,2020